Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

Paper of the month

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

    James Larkin, M.D., Ph.D., Vanna Chiarion-Sileni, M.D., Rene Gonzalez, M.D., Jean Jacques Grob, M.D., C. Lance Cowey, M.D., Christopher D. Lao, M.D., M.P.H., Dirk Schadendorf, M.D., Reinhard Dummer, M.D., Michael Smylie, M.D., Piotr Rutkowski, M.D., Ph.D.

    Background Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] checkpoint inhibitor) have...
  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert, M.D., Ph.D., Jacob Schachter, M.D., Georgina V. Long, M.D., Ph.D., Ana Arance, M.D., Ph.D., Jean Jacques Grob, M.D., Ph.D., Laurent Mortier, M.D., Ph.D., Adil Daud, M.D. et al.

    Background The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell...

    Editors’ comment: Dr. Paolo Ascierto
    Immunotherapy represents one of the fastest growing areas in oncology. The two main inhibitory...

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037)

    A randomised, controlled, open-label, phase 3 trial

    Jeffrey S Weber et al. Lancet Oncol 2015;16:375–84

    Editorial comment by Prof. R. Dummer:
    The treatment of patients who progressed after ipilimumab and/or targeted therapy is a...

  • Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

    Alexandra Snyder, M.D., Vladimir Makarov, M.D., Taha Merghoub, Ph.D., et al.

    N Engl J Med 2014; 371:2189-2199December 4, 2014DOI: 10.1056/NEJMoa1406498

    Editorial comment by Dr. J. Larkin:
    Whole-exome sequencing was undertaken on tumours and matched blood samples of 64 patients...

  • Nivolumab in Previously Untreated Melanoma without BRAF Mutation

    Caroline Robert, M.D., Ph.D., Georgina V. Long, M.D., Ph.D., Benjamin Brady, M.D., Et al

    N Engl J Med 2014, E-pub November 16, 2014,

    Editor's comments: Prof Paolo A. Ascierto
    Nivolumab is a fully human IgG4 anti PD-1 antibody that selectively blocks the interaction...

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    Georgina V. Long, M.D., Ph.D., Daniil Stroyakovskiy, M.D., Helen Gogas, M.D., Evgeny Levchenko, M.D., Filippo de Braud, M.D., James Larkin, M.D., Claus Garbe, M.D., Ph.D., Thomas Jouary, M.D., Axel Hauschild, M.D., Ph.D., Jean Jacques Grob, M.D., Ph.D., V

    N Engl J Med 2014; 371:1877-1888November 13, 2014DOI: 10.1056/NEJMoa1406037

    Editorial comment by Prof. R. Dummer:
    This month we have decided to present two papers. Both papers were published...

  • Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

    James Larkin, M.D., Ph.D., Paolo A. Ascierto, M.D., Brigitte Dréno, M.D., Ph.D., Victoria Atkinson, M.D., Gabriella Liszkay, M.D., Michele Maio, M.D., Mario Mandalà, M.D., Lev Demidov, M.D., Daniil Stroyakovskiy, M.D., Luc Thomas, M.D., Ph.D., Luis de la

    N Engl J Med 2014; 371:1867-1876November 13, 2014DOI: 10.1056/NEJMoa1408868
  • eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

    Lise Boussemart, Hélène Malka-Mahieu, Isabelle Girault, Delphine Allard, Oskar Hemmingsson, Gorana Tomasic, Marina Thomas, Christine Basmadjian, Nigel Ribeiro, Frédéric Thuaud, Christina Mateus, Emilie Routier, Nyam Kamsu-Kom, Sandrine Agoussi, Alexander

    Nature 513, 105–109 (04 September 2014) doi:10.1038/nature13572

    Editorial comment by professor Reinhard G. Dummer:
    A French research group headed by Dr. Vagner has investigated molecular alterations...

  • Combination of vemurafenib and cobimetinib in patients with advanced BRAF V600-mutated melanoma: a phase 1b study

    Antoni Ribas, Rene Gonzalez, Anna Pavlick, Omid Hamid, Thomas F Gajewski, Adil Daud, Lawrence Flaherty, Theodore Logan, Bartosz Chmielowski, Karl Lewis, Damien Kee, Peter Boasberg, Ming Yin, Iris Chan, Luna Musib, Nicholas Choong, Igor Puzanov, Grant A Mc

    Original Research Article The Lancet Oncology, Volume 15, Issue 9, August 2014, Pages 954-965

    Editor's comments:
    This is a dose-escalation phase I trial which enrolled 129 patients with advanced melanoma BRAFV600 mutant; all...

  • GNAQ/11 Mutations in Uveal Melanoma: Is YAP the Key to Targeted Therapy?

    Matthew G. Field, J. William Harbour

    Cancer Cell, 6, 25, pages 714 - 715

    Editor's comments:
    By Prof. Reinhard Dummer: Finally a target for the treatment of Uveal melanoma? Ocular melanomas are the...

Pages